Method for preparing metformin hydrochloride controlled-release pellet preparation

A technology of metformin hydrochloride and sustained-release pellets, which is applied in drug combination, block delivery, metabolic diseases, etc., can solve the problems of unsatisfactory drug compliance of patients, imperfect preparation process and equipment of double-layer osmotic pump technology, and achieve Small differences in individual bioavailability, good dosing regimen and curative effect, good absorption effect

Inactive Publication Date: 2013-12-04
中国人民解放军第150中心医院
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The patent document with the patent application number 20101051.527.0 discloses a compound preparation composed of pioglitazone hydrochloride and metformin hydrochloride double-layer osmotic pump controlled-release tablet, which consists of a drug-containing layer and a booster layer in sequence from the inside to the outside in terms of structural composition Tablet core, isolation coat layer, controlled-release coating film with release holes, pioglitazone hydrochloride immediate-release layer and optional aesthetics coat, the invention adopts double-layer osmotic pump controlled-release technology to improve the later release of metformin hydrochloride, but The preparation process and equipment of the existing double-layer osmotic pump technology are still not perfect, and the invention has the feasibility problem of industrial production, and the addition of the booster in the double-layer osmotic pump tablet limits the content of each active drug. The effective dose can only be achieved by taking multiple tablets, which is not ideal in improving patients' compliance with medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The metformin hydrochloride sustained-release pellets are composed of two parts: a drug-containing pellet core and a sustained-release layer; the drug-containing pellet core is composed of metformin hydrochloride, a filler, and a binder; the sustained-release layer is composed of a sustained-release material and a pore-forming agent; the composition weight percentage It is: 40.0-70.0% metformin hydrochloride, 30.0-75.0% filler, 0.4-5.0% binder, 4.7-16.7% slow-release material, 0.01-1.0% porogen. The sum is 100%.

Embodiment 2

[0024] The composition weight percentage is: metformin hydrochloride 44.5-67.4%, microcrystalline cellulose 23.0-66.0%, sucrose 11.3-18.5%, hypromellose 1.3-4.2%, acrylic resin aqueous dispersion Eudragit 5.3-14.2% %, hypromellose 0.01-0.7%, the sum of the above components by weight is 100%.

Embodiment 3

[0026] The composition weight percentage is: metformin hydrochloride 46.0-64.8%, microcrystalline cellulose 43.0-72.6%, hypromellose 0.8-4.6%, ethyl cellulose aqueous dispersion product Surelease 5.7-14.7%, lauryl Sodium sulfate 0.01-0.6%, the sum of the above components by weight is 100%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for preparing a metformin hydrochloride controlled-release pellet preparation. A metformin hydrochloride controlled-release pellet is composed of a drug-contained pellet core and a controlled-release layer. The drug-contained pellet is composed of metformin hydrochloride, a filling agent and an adhesive. The controlled-release layer is composed of a controlled-release material and a pore-foaming agent. The metformin hydrochloride controlled-release pellet is mixed with pioglitazone hydrochloride controlled-release pellets to obtain the compounded metformin hydrochloride / pioglitazone hydrochloride controlled-release pellet preparation which achieves the ideal effect of regulating a blood sugar level, can reduce toxic and side effects of drugs, can achieve the effect of continuously and stably reducing the blood sugar level in the body, and facilitate improvement of the compliance of a patient. The compounded metformin hydrochloride controlled-release pellet preparation has high bioavailability and stable blood concentration. Clinical effects are effectively improved and a better dosage regimen and a better treatment effect are provided for domestic and overseas diabetics.

Description

technical field [0001] The invention relates to the technical field of diabetes pharmacy, in particular to a compounding method of metformin hydrochloride sustained-release pellet preparation. [0002] Background technique [0003] Diabetes (diabetes) is a sugar, protein, Syndrome of a series of metabolic disorders including fat, water and electrolytes. Clinically, hyperglycemia is the main feature. In typical cases, symptoms such as polyuria, polydipsia, polyphagia, and weight loss may occur, namely "three excesses and one deficiency". Once diabetes (blood sugar) is not well controlled, it will cause complications and lead to kidney disease Diabetes, eyes, feet and other parts of the failure of the disease, and can not be cured; diabetes has become a common and frequently-occurring disease in my country and the world, and has become one of the diseases with the highest morbidity and mortality. Diabetes is divided into two types, type 1 is insulin-dependent diabetes and ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K31/155A61P3/10
Inventor 崔新刚梁延春王颖莹高春芳吴英超
Owner 中国人民解放军第150中心医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products